CombiGene selects AmbioPharm as peptide CDMO partner for their COZY01 pain project
Roche’s Spark Therapeutics unit is offering up to $328.5 million in biobucks for CombiGene’s gene therapy for epilepsy, which has a specific focus on drug-resistant forms of the condition.
Complete production and quality assurance of the plasmids to be used in the GMP production of CG01.